Topic: authorized generics
Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.
Novo Nordisk combines rivals Sanofi and Eli Lilly's recent measures in two insulin cost-cutting projects in the U.S.
When PDL BioPharma’s blood-pressure medicine faced the threat of a generic rival this year, the company used its own generic to fend off competitors.
Lilly could relieve itself of some public pressure with the authorized Humalog generic, but will Sanofi and Novo follow with Lantus and NovoLog?
The move comes as Lilly and the other two big diabetes drugmakers face increasing political pressure on rising insulin prices.
Years after Teva entered an FTC settlement on "pay-for-delay" deals, the parties on Tuesday expanded the agreement.
Thanks to high rebates and payer hardball, Gilead is in a tough spot with its hepatitis C drugs, including its all-genotype treatment Epclusa and the once-high-flying Harvoni. In response, the company did something previously unheard of in pharma.
Gilead and Express Scripts have clashed in hepatitis C before, but now that Gilead plans authorized generics of its own drugs, Express Scripts is on board.
Dr. Reddy's moved ahead with an "at risk" launch of Indivior's top drug, but now a court has put the rollout on hold.